CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 473 participants.

Also called NCT03636269

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 473 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03636269
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Czechia, Germany, Hungary, New Zealand, Poland, South Korea, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03636269. Randomized; triple masking; primary purpose treatment. Start 2018-07-17 (actual); primary completion 2020-03-30 (actual). Results posted on 2022-04-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Acronym
KALM-2
Condition
Uremic Pruritus
Intervention (Drug)
CR845 0.5 mcg/kg
Intervention (Drug)
Placebo
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03636269
Content hash
87a50e6f36eb68ffba68bc57d0e452b23ac29ebdd3678a93e11caed45b2b8331